secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-10-15T13:30:14+00:00
Accession:  0001493152-26-047168
Event type: other_material
Sentiment:  positive
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

bioAffinity to sponsor CHEST 2026 Learning Theater on CyPath Lung and asthma/COPD research
--------------------------------------------------------------------------------

- bioAffinity Technologies (Nasdaq: BIAF, BIAFW) will sponsor a Learning Theater at CHEST 2026 on Oct. 21, 2026, 12:30-1:15 p.m. MST in Phoenix.
- Chief Medical Officer Gordon H. Downie, MD, PhD, will present on CyPath Lung for lung cancer risk stratification and pulmonary nodule management.
- CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% negative predictive value for small indeterminate nodules under 20 mm.
- Presentation will discuss preliminary data from an investigational asthma/COPD lung inflammation test.
- Medical and Scientific Advisory Board to meet; members include David Hill, David Ost, Daniel Sterman, Sheila Habib, J. Scott Ferguson, Neil Alexis and Sandeep Bansal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226047168/0001493152-26-047168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226047168/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-047168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer